Pharmaceutical composition for inhibiting osteoclast growth
A pharmaceutical composition for inhibiting osteoclast growth is disclosed in the present invention. The pharmaceutical composition includes a compound represented by a formula (I), and a pharmaceutically acceptable salt and carrier: wherein R 1 , R 2 , R 3 , R 4 can be one selected from a group consisting of hydrogen, halogen, C 1 ˜C 10 alkyl group, C 2 ˜C 10 alkynyl group, amino group, haloalkyl group and sulfonamide group.
1. A pharmaceutical composition for inhibiting osteoclast precursor growth comprising N-(3-ethynylphenyl)-2-hydroxybenzamide, a pharmaceutically acceptable salt, and a carrier.
2. The pharmaceutical composition according to claim 1 , wherein the carrier is an excipient, a diluent, a thickener, a filler, a binder, a disintegrant, a lubricant, a oleaginous base, an non-oleaginous base, a surfactant, a suspending agent, a coagulant, an auxiliary agent, a preservative, an anti-oxidant, a stabilizer, a colorant or a flavoring.
3. The pharmaceutical composition according to claim 2 , wherein the excipient comprises microcrystalline cellulose, polyvinylpyrrolidone, corn starch, modified starches, sodium starch glycolate, resin, gelatinized starches, carbohydrate, polyethylene glycol, polyvinyl alcohol, hydroxypropyl cellulose, methylcellulose, hydroxymethyl cellulose or hydroxypropyl methylcellulose.
4. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable salt is a physiologically acceptable with inorganic/organic acid or base.
5. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a powder, a grain, a liquid, a colloid or a paste.
6. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is formulated for oral administration, transcutaneous administration, injection administration or inhalation administration.